According to reports that were released last Friday – 29th of August 2014, Keay Nakae, who is an analyst of the Ascendiant Capital Markets, reiterated the Repros Therapeutics. He also raised its price to $25 from $23. The decision of Keay Nakae to reiterate the Buy rating on the Repros Therapeutics followed the positive topline results from of their studies.
The company also believes that in the future, the positive results of these studies will be able to help them back up the possible labeling claims for the superiority of the Androxal product over the Androgel product. Once these results support the claim, there is no question that this will do good in improving the commercial attractiveness of the Androxal product. They are currently hoping now that the ZA-304 results will turn out as good as the ZA-305 results.